Periodontitis is a chronic infectious disease affecting human health and oral wellbeing, with Porphyromonas gingivalis as a key pathogen. Effective local therapies are essential to improve clinical outcomes and reduce disease burden, with implications for public health. To evaluate the clinical and microbiological efficacy of subgingivally delivered ranitidine hydrogel as an adjunct to scaling and root planing in Stage II Grade A periodontitis. Fifty systemically healthy patients (30–60 years) were divided into control (scaling and root planing) and test (scaling and root planing + ranitidine hydrogel) groups. Clinical parameters—plaque index, gingival index, probing pocket depth, and clinical attachment level—were recorded at baseline and 3 months. Subgingival P. gingivalis levels were assessed via real-time PCR. Statistical significance was set at p < 0.05. Both groups showed significant improvement in clinical and microbiological parameters (p < 0.05). The test group demonstrated greater reductions in clinical indices and P. gingivalis load compared to the control (p < 0.05). Subgingival ranitidine hydrogel enhanced non-surgical periodontal therapy outcomes, reducing microbial burden and supporting its role as an adjunctive medicine in managing periodontal disease, thereby promoting oral health, wellbeing, and broader public health.
